NCT00023699 2013-06-24
Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
National Cancer Institute (NCI)
National Cancer Institute (NCI)